124 related articles for article (PubMed ID: 15246194)
1. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience.
Kommareddy A; Coplin MA; Gao F; Behnken D; Romvari E; Read W; Govindan R
Lung Cancer; 2004 Aug; 45(2):221-5. PubMed ID: 15246194
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
3. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Spigel DR; Hainsworth JD; Burkett ER; Burris HA; Yardley DA; Thomas M; Jones SF; Dickson NR; Scullin DC; Bradof JE; Rubinsak JR; Brierre JE; Greco FA
Clin Lung Cancer; 2005 Sep; 7(2):127-32. PubMed ID: 16179100
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
6. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Hata A; Katakami N; Yoshioka H; Fujita S; Kunimasa K; Nanjo S; Otsuka K; Kaji R; Tomii K; Iwasaku M; Nishiyama A; Hayashi H; Morita S; Ishida T
Lung Cancer; 2011 Nov; 74(2):268-73. PubMed ID: 21529987
[TBL] [Abstract][Full Text] [Related]
8. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
[TBL] [Abstract][Full Text] [Related]
9. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
Thongprasert S; Soorraritchingchai S; Chewaskulyong B; Charoentum C; Munprakan S
J Med Assoc Thai; 2006 Feb; 89(2):152-9. PubMed ID: 16579000
[TBL] [Abstract][Full Text] [Related]
11. Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Reck M; Gatzemeier U
Lung Cancer; 2005 Oct; 50(1):107-14. PubMed ID: 15985306
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
13. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
[TBL] [Abstract][Full Text] [Related]
15. Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Pallis AG; Christofillakis Ch; Tselepatiotis E; Agelaki S; Vamvakas L; Souglakos J; Vardakis N; Kalykaki A; Kotsakis A; Argiraki A; Mavroudis D; Georgoulias V
Lung Cancer; 2007 Jan; 55(1):101-7. PubMed ID: 17049673
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
Moore AM; Einhorn LH; Estes D; Govindan R; Axelson J; Vinson J; Breen TE; Yu M; Hanna NH
Lung Cancer; 2006 Apr; 52(1):93-7. PubMed ID: 16488055
[TBL] [Abstract][Full Text] [Related]
18. Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
Chen X; Li W; Hu X; Geng Y; Wang R; Yin Y; Shu Y
Biomed Pharmacother; 2011 Dec; 65(8):542-6. PubMed ID: 21840160
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
O'Byrne KJ; Danson S; Dunlop D; Botwood N; Taguchi F; Carbone D; Ranson M
J Clin Oncol; 2007 Aug; 25(22):3266-73. PubMed ID: 17664473
[TBL] [Abstract][Full Text] [Related]
20. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]